Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$1.24M$1.24M+0.8% vs Q1 2023 Net Income-$2.39M-$2.39MN/M vs Q1 2023 EPS Diluted-$0.27-$0.27N/M vs Q1 2023 Operating Income-$2,549,017N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
Margins · derivedOperating margin-204.9%+144.2 pt vs Q1 2023
Net margin-192.3%+210.1 pt vs Q1 2023
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end